Development and pharmacological analysis of therapeutic drugs for conformation diseases and prion diseases
Development and pharmacological analysis of therapeutic drugs for conformation diseases and prion diseases
批准号:
14207030
负责人:
DOH-URA Katsumi
金额:
$28.12万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004
中文摘要
本研究的目的不仅是开发预防和治疗各种构象疾病的药物,如普鲁恩病、阿尔茨海默病和淀粉样变性,而且阐明作用于异常构象蛋白的药物的药理作用。通过三种体外试验,筛选出许多无神经毒性、有效抑制每种淀粉样蛋白聚集和神经毒性的候选化合物。这些化合物包括喹啉类化合物、苯并噻唑类化合物、非喹啉螯合化合物、刚果红相关化合物、硫酸多糖等。通过表面等离子体共振或圆二色谱研究了候选化合物对淀粉样蛋白多肽的作用机制。结果表明,大多数化学物质可以与…疏水口袋中核心β-折叠结构的疏水氨基酸序列相互作用更多的是淀粉样蛋白。他们还表明,这些化学物质的疏水结合强度与抑制淀粉样蛋白聚集的有效性相关,但并不总是与抑制神经毒性的有效性相关。在三种构象疾病模型小鼠中检测了几种渗透到大脑的化学物质。结果表明,化合物A口服给药是安全有效的预防和治疗药物,而化合物MC一次皮下注射更安全,在预防和治疗方面是最有益的。然而,体内有一些无效的化学物质,甚至很容易渗透到大脑,结合到由异常构象蛋白组成的沉积上。多个体外和体内实验表明,这种不一致可能是由于异常蛋白质和宿主因子(S)的构象变化引起的。研究结果表明,构象疾病药物的开发研究现在已经为下一阶段的翻译研究做好了准备。较少
英文摘要
This research was aimed to not only develop prophylactic and therapeutic drugs for any type of conformation diseases such as prion diseases, Alzheimer's disease and amyloidoses, but also clarify the pharmacology of the drugs acting on the abnormal conformation proteins.Using three in-vitro assays, candidate chemicals were screened, and many potent candidates which were non-neurotoxic and effective to inhibit both the aggregation of each amyloidotic protein and the neurotoxicity. These included quinoline compounds, benzothiazole compounds, non-quinoline chelatirig chemicals, Congo red related chemicals, sulfated polysaccharides and so on.The mechanism of action by the candidate chemicals on amyloidotic peptides derived from each of the amyloidotic proteins was examined by either surface plasmon resonance or circular dicroism. The results suggested that most of the chemicals could interact with a hydrophobic amino acid sequence of the core beta sheet structure in a hydrophobic pocket of … More the amyloidotic proteins. They also showed that strength of hydrophobic bonding by the chemicals was correlated with effectiveness in inhibiting the aggregation of the amyloidotic proteins but was not always correlated with effectiveness in inhibiting the neurotoxicity.Several of the chemicals which penetrated into the brain were assayd in three types of conformation disease model mice. The results showed that compound A in per oral administration was safe and very effective as a prophylactic and therapeutic drug, and also compound MC in even one shot subcutaneous administration was much safer and the most beneficial in the prophylaxis and therapeutics. However, there were some ineffective chemicals in vivo which even easily penetrated into the brain and bound to the depositions composed of the abnormal conformation proteins. Several in-vitro and in-vivo experiments suggested that this inconsistency might be caused by conformational variety of the abnormal proteins and host factor(s).The findings of the research indicate that the research for the development of conformation disease medicine is now ready for the next stage of translational research. Less
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
プリオン蛋白蓄積性疾患の診断プローブ及び治療薬としてのベンゾオキサゾール環含有化合物
含苯并恶唑环的化合物作为朊病毒蛋白贮积病的诊断探针和治疗剂
DOI:
--
发表时间:
2002
期刊:
影响因子:
--
作者:
[]
通讯作者:
Accumulation of prion protein in the degenerated muscle fibers of experimental chloroquine myopathy : in vivo model for deposition of prion protein in non-neuronal tissues.
实验性氯喹肌病的退化肌纤维中朊病毒蛋白的积累:朊病毒蛋白在非神经元组织中沉积的体内模型。
DOI:
--
发表时间:
2004
期刊:
Laboratory Investigation 84
影响因子:
--
作者:
[Furukawa H, et al.]
通讯作者:
et al.
プリオン病発症予防剤とそれを含む食品添加剤及び飼料添加剤
朊病毒疾病预防剂以及含有该预防剂的食品添加剂和饲料添加剂
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[]
通讯作者:
Development of anti-prion disease drugs.
抗朊病毒病药物的开发。
DOI:
--
发表时间:
2003
期刊:
Shinkeikenkyu-no-shinpo (Jpn) 47
影响因子:
--
作者:
[Sasaki K, et al., 堂浦克美, 堂浦克美, Doh-ura K.]
通讯作者:
Doh-ura K.
プリオン病の治療薬開発
朊病毒疾病治疗药物的开发
DOI:
--
发表时间:
2002
期刊:
医学のあゆみ 203(10)
影响因子:
--
作者:
[Sasaki K, et al., 堂浦克美, 堂浦克美, Doh-ura K., 堂浦克美]
通讯作者:
堂浦克美
共 25 条
Elucidation of the epigenetic gene regulation related to the inhibition of prion formation
-
批准号:24659424
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2012
-
负责人:DOH-URA Katsumi
-
依托单位:
Investigation on host defense mechanism and search for new therapeutic targets against prion diseases
-
批准号:22390172
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.9万
-
财政年份:2010
-
负责人:DOH-URA Katsumi
-
依托单位:
Research of therapeutic strategy applying to both prion diseases and Alzheimer's disease
-
批准号:19390234
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.06万
-
财政年份:2007
-
负责人:DOH-URA Katsumi
-
依托单位:
Development of prophylactic and therapeutic anti-prion drugs for the patients at high risks
-
批准号:13557118
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.51万
-
财政年份:2001
-
负责人:DOH-URA Katsumi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
-
批准号:22077118
-
项目类别:面上项目
-
资助金额:63.0万元
-
批准年份:2020
-
负责人:高楠
-
依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
-
批准号:81870666
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:王海燕
-
依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
-
批准号:81601123
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:都瑾
-
依托单位:
APOC1,CLU,SORL1,APOE变异通过调控脂代谢和Abeta水平影响痴呆发病机理的研究
-
批准号:81460203
-
项目类别:地区科学基金项目
-
资助金额:47.0万元
-
批准年份:2014
-
负责人:胡才友
-
依托单位:
TAG1/APP信号通路调控的miRNA及其在神经前体细胞增殖和分化中的作用机制
-
批准号:31171313
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:马全红
-
依托单位:
细胞型朊蛋白介导Aβ寡聚体神经毒性的信号转导机制研究
-
批准号:81100246
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:张海英
-
依托单位:
EndophilinB1对APP及A-beta的调控作用在阿尔茨海默病中的机制性研究
-
批准号:81171017
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:万峻
-
依托单位:
STAT3对miRNA-200家族的转录调控作用在阿尔茨海默病发病机理中的功能性研究
-
批准号:81000465
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:万峻
-
依托单位:
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
-
批准号:30971012
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2009
-
负责人:刘瑞田
-
依托单位:
天然药物诱导神经元NEP表达上调及降低Aβ缓解Alzheimer症作用机制的研究
-
批准号:30670746
-
项目类别:面上项目
-
资助金额:8.0万元
-
批准年份:2006
-
负责人:崔行
-
依托单位: